SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as the stock price jumped following news that CEO Elon Musk purchased a significant amount of shares, his first open-market buy since 2020. The community is discussing whether this purchase signals a short squeeze to $500 and how it impacts the stock's technical analysis. Many view this as a bullish sign, while some remain skeptical, citing concerns about valuation and Musk's overall strategy.

Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational portable neuromodulation stimulator, that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded on March 13, 2014 and is headquartered in Newtown, PA.

Helius Medical Technologies Inc - Ordinary Shares - Class A

Helius Medical Technologies Inc

HSDT is trending due to a recent surge following positive trial results for its stroke therapy, with community members debating whether to hold for a potential FDA submission catalyst or take profits amidst concerns of manipulation and past reverse splits. The stock's low float is fueling discussions about a potential short squeeze, while some caution against a possible offering. The community is closely watching for news that could drive the price higher, as well as the company's next move.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies behind the project's resilience and upcoming developments, including a Bifinance listing and airdrop. Community members highlight the project's organic growth, transparency, and active development team. Bullish sentiment is high, with many anticipating new ATHs and increased exposure for this Solana-based token.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Atyr Pharma Inc

aTyr Pharma, Inc

Anticipation is building around ATYR as traders await the release of Phase 3 trial data, expected mid-September, with the community buzzing about potential data leaks and speculating on the timing of the results. Community members are weighing bullish and bearish perspectives, debating the likelihood of trial success, and analyzing the potential for a short squeeze. With a binary event on the horizon, ATYR is seeing increased volatility and high options premiums, driving significant conversation among investors.

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Asset Entities Inc - Ordinary Shares - Class B

Asset Entities Inc.

Asset Entities Inc. is trending due to its recent merger with Strive and a planned pivot towards Bitcoin asset management, creating excitement around a potential short squeeze. Some platforms are experiencing trading halts due to the CUSIP change, while community members debate holding strategies amidst high short interest and borrow fees. The stock's association with figures like Vivek Ramaswamy is also fueling speculation and interest.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending due to Needham's raised price target and overall excitement in the quantum computing sector, sparking discussions about its potential and possible acquisitions. Community members debate the company's valuation, long-term prospects, and potential to become the "next NVDA", while also discussing upcoming catalysts like the analyst day and potential government contracts. The stock's breakout and trading volume are also contributing to the increased attention.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending amid discussions about its AI strategy and potential benefits from its partnership with OpenAI. Community members are analyzing chart patterns, with some anticipating a breakout and others highlighting potential resistance levels. Broader conversations touch on Microsoft's position within the tech sector and its competition with other major players in the AI space.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending as retail investors anticipate new peaks, with community members actively discussing potential price movements and key resistance levels. The stock is also gaining attention due to its participation in the White House's eVTOL pilot program and speculation around defense contracts. Community sentiment suggests anticipation for a potential squeeze, with some expressing frustration over the stock's performance compared to sector peers.

Investment Managers Series Trust II - Tradr 2X Short TSLA Daily ETF

Tradr 2X Short TSLA Daily ETF

TSLQ is trending as traders discuss potential downside for Tesla (TSLA) amid ongoing debate around its valuation, sales, and the impact of Elon Musk's actions. Community members are actively strategizing entry points and discussing potential profit targets, considering both technical analysis and broader market sentiment. Some traders mention potential short-term gains while others suggest Tesla fundamentals do not justify the current market value.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab ($RKLB) is trending due to positive momentum, with the stock hitting new 52-week highs and breaking through resistance levels, fueling bullish sentiment. The community is discussing potential for further gains, eyeing targets like $60 and beyond, driven by the anticipation around the Neutron rocket and recent mission successes. Some are noting increased call option activity and institutional investment as potential drivers for continued upward movement.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biodesix, Inc. (BDSX) Reports Q2 Loss, Tops Revenue Estimates

Biodesix (BDSX) delivered earnings and revenue surprises of -14.29% and +7.34%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Avantor, Inc. (AVTR) Q2 Earnings Lag Estimates

Avantor (AVTR) delivered earnings and revenue surprises of -4.00% and +0.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Biodesix Inc’s shares jumped Wednesday, driven by a sizable insider purchase and heightened retail investor optimism, even as Scotiabank cut its price target to $2 from $3 after the company reported weaker-than-expected first-quarter (Q1) revenue.The stock surged 45.9% to close at $0.4 on Wednesday, before falling 11.4% in after-hours trading to $0.35.Biodesix’s first-quarter revenue reached $17.96 million, below the analysts' anticipated $19.5 million consensus estimate.The lowered target also reflects a downward revision of the full-year 2025 revenue guidance amid a strategic commercial shift.Biodesix revised its 2025 revenue guidance to $80 million–$85 million, down from earlier forecasts.&nbsp;The company posted Q1 2025 revenue growth of 21% year-over-year, with diagnostic testing revenue rising 18% and development services revenue surging 61%.&nbsp;Gross margins improved to 79.4%, and net loss narrowed by 18%.&nbsp;CEO Scott Hutton said that a commercial pilot in late 2024 expanded outreach to pulmonologists and primary care physicians managing roughly half of lung nodule patients.&nbsp;After the pilot’s success, Biodesix restructured its sales team into a territory-based model across multiple specialties, delaying commercial expansion by about one quarter and contributing to the revised guidance.Despite the revenue miss and guidance cut, Biodesix reiterated expectations to achieve adjusted EBITDA positivity by Q4 2025, supported by strong gross margins and cost efficiencies.&nbsp;Over the past month, multiple research firms have lowered their price targets on Biodesix amid a challenging outlook.&nbsp;Notably, Canaccord cut its target twice — from $3.50 to $2.50 and further down to $1.50 — citing tariffs, funding uncertainty, and below-expectation Q1 results.&nbsp;Other firms,&nbsp;such as Lake Street and TD Cowen, lowered their targets to $2 following a Q1 revenue miss and salesforce restructuring.Craig-Hallum dropped its target to $1.50, anticipating further sell-offs, and William Blair downgraded the stock to ‘Market Perform’ due to slower sales-representative hiring and higher attrition.Meanwhile, the company said Tuesday that Jack W. Schuler, a 10% owner and director, executed a purchase of 4.7 million shares on May 16 for $1.3 million.&nbsp;Schuler previously served as&nbsp;president and&nbsp;chief operating officer of Abbott Laboratories before joining Ventana.&nbsp;Currently, Schuler controls 35.9 million common shares, all held indirectly.&nbsp;On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 510% surge in 24-hour message volume.One user urged investors to "trust the process" and maintain patience, citing Biodesix’s potential to meet compliance standards and reach profitability organically by year-end.&nbsp;<stembedurl>https://stocktwits.com/Trader1397/message/615454686</stembedurl>Meanwhile, others expressed optimism about Schuler’s recent sizable insider purchase, emphasizing his strong healthcare background and suggesting his stake could help spark renewed investor interest and upward momentum in the stock.<stembedurl>https://stocktwits.com/Babybillysbiblebonker/message/615448768</stembedurl>The stock has declined 73.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Biodesix logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Biodesix Jumps 46% As Insider Buying, Retail Optimism Offset Scotiabank Target Cut

Investors cheered a 4.7 million share insider purchase and rallied behind the company’s push toward Q4 EBITDA positivity, offsetting Scotiabank’s price target cut to $2 after a Q1 revenue miss and lowered 2025 guidance.

Equity

Biodesix, Inc. (BDSX) Reports Q1 Loss, Misses Revenue Estimates

Biodesix to Report Third Quarter 2024 Financial Results on November 1, 2024

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the third quarter ended September 30...

Biodesix Announces New Data Presentation at CHEST 2024 Annual Meeting and the Launch of a Complementary Clinical Study

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new data will be presented at the CHEST Annual Meeting 2024 in Boston...

Biodesix to Present at Two Investor Conferences in September

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that members of the Biodesix management team will present at two upcoming investor...

Biodesix to Report Second Quarter 2024 Financial Results on August 7, 2024

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced today that it will release financial results for the second quarter ended June 30, 2024 after the close of trading on...

Biodesix Named to Inc. Magazines 2024 Best Workplaces

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, is honored to announce it has been named to Inc. Magazines Best Workplaces list. The ranking is a result of a comprehensive...

Biodesix to Participate in Two Investor Conferences in June

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer, will participate in two upcoming investor...

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.

Current Price	$7.50
Prev Close	$8.26
Open	$8.24
Dividend Yield	0.00%
50-Day Moving Average	$0.3922
Beta	0.77
Avg. Volume	1.41M
PE Ratio	-1.34

52-Week High	$1.85
52-Week Low	$0.1718
Market Capitalization	$55M
EPS (Annual)	-$0.3311
Price to Book	48.34
Revenue Per Employee	$261,256.41
Enterprise Value/EBITDA	N/A

BDSX
Biodesix Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BDSX News

BDSX Biodesix Inc